ArticleClinical ophthalmology (Auckland, N.Z.)2025
Prevalence, Incidence, and Treatment Characteristics of Primary Open-Angle Glaucoma Among Medicare Fee-for-Service Beneficiaries.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to describe Medicare FFS beneficiaries with prevalent and incident POAG, and to determine their demographic characteristics. Secondary objectives included describing POAG prescription rates, prescribers of POAG therapy, and dry eye disease rates among POAG prevalent beneficiaries. Patients and Methods: The study was a retrospective cohort analysis using de-identified Medicare FFS medical and pharmacy claims and enrollment data (Parts A/B/D) spanning from January 1, 2016, to December 31, 2021. Medicare FFS beneficiaries were included in the analysis if they were diagnosed or treated for POAG, 65 years of age or older, and continuously enrolled for at least 24 months. Beneficiaries were identified between January 1, 2017, and December 31, 2021, allowing for a 12-month baseline to categorize patients as incident or prevalent. Comorbid dry eye disease and prescription POAG therapies were also identified. Prescriber NPIs were used to classify prescriber types. Results: From 2017 to 2021, 5.5-6.2% of Medicare FFS beneficiaries were identified with prevalent POAG, with ~1% categorized as incident. A higher proportion of POAG beneficiaries were older and/or Black. At least 81% received POAG prescription therapy each year, with ophthalmologists as most frequent prescribers. Comorbid dry eye was documented in 16.4-18.7% of beneficiaries with prevalent POAG, and in 11.8-13.6% of beneficiaries with incident POAG. Conclusion: A significant proportion of Medicare FFS beneficiaries have POAG. While most people with POAG received some type of prescription therapy each year, a notable proportion of individuals had no form of prescription POAG therapy identified. Given higher rates of dry eye disease in people with glaucoma, dry eye disease screening and care among beneficiaries with POAG should be promoted. Future research should evaluate treatment patterns and outcomes among Medicare FFS beneficiaries with comorbid POAG and dry eye disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.